利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

805 条记录 (耗时 0.036 秒)

    Carboxylic acids
    12.
    发明授权
    Carboxylic acids 失效
    羧酸

    公开(公告)号：US07253178B2

    公开(公告)日：2007-08-07

    申请号：US10469173

    申请日：2002-03-27

    申请人： Hitoshi Harada ,  Masanobu Shinoda ,  Richard Clark ,  Fumiyoshi Matsuura ,  Eita Emori ,  Shunji Kasai ,  Hideki Yoshitomi ,  Kazuto Yamazaki ,  Takashi Inoue ,  Sadakazu Miyashita ,  Taro Hihara

    发明人： Hitoshi Harada ,  Masanobu Shinoda ,  Richard Clark ,  Fumiyoshi Matsuura ,  Eita Emori ,  Shunji Kasai ,  Hideki Yoshitomi ,  Kazuto Yamazaki ,  Takashi Inoue ,  Sadakazu Miyashita ,  Taro Hihara

    IPC分类号： A61K31/435 ,  A61K31/44 ,  C07D211/72 ,  C07D211/70

    CPC分类号： C07D213/64 ,  C07D213/79

    摘要： The present invention provides a novel carboxylic acid derivative, a salt thereof or a hydrate of them which is useful as an insulin sensitizer, and a medicament comprising the derivative as the effective ingredient. More specifically, it provides a carboxylic acid compound represented by the formula (I), a salt thereof or a hydrate of them. In the formula, Ar represents a 6- to 14-membered aromatic ring group which may have at least one substituent; R1, R2, R3, R4, R5, R6, R7 and R8 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-6 alkyl group or a C1-6 alkoxy group; X represents an oxygen atom or a methylene group; Y represents a group represented by the formula (II) or (III): (wherein Z represents a group represented by the formula (IV): (wherein R9, R10, R11 and R12 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-6 alkyl group or a C1-6 alkoxy group)); m is 0 or 1; and n is 0 or 1.

    摘要翻译： 本发明提供了可用作胰岛素敏化剂的新型羧酸衍生物，其盐或其水合物，以及包含该衍生物作为有效成分的药物。 更具体地，它提供由式（I）表示的羧酸化合物，其盐或它们的水合物。 在该式中，Ar表示可以具有至少一个取代基的6至14元芳环基团; R 1，R 2，R 3，R 4，R 5， R 6，R 7和R 8彼此相同或不同，并且各自表示氢原子，卤素原子， 羟基，C 1-6烷基或C 1-6烷氧基; X表示氧原子或亚甲基; Y表示由式（II）或（III）表示的基团：（其中Z表示由式（IV）表示的基团：（其中R 9，R 10， >，R 11和R 12彼此相同或不同，并且各自表示氢原子，卤素原子，羟基，C 1 -C 12烷基， 1-6烷基或C 1-6烷氧基））; m为0或1; n为0或1。

    Mammalian prickle gene
    16.
    发明申请
    Mammalian prickle gene 审中-公开
    哺乳动物刺刺基因

    公开(公告)号：US20060292669A1

    公开(公告)日：2006-12-28

    申请号：US10536586

    申请日：2003-11-28

    申请人： Masakazu Takeuchi ,  Keiko Sato ,  Yoshimasa Sakamoto ,  Maki Tawarada ,  Toshihisa Ohtsuka

    发明人： Masakazu Takeuchi ,  Keiko Sato ,  Yoshimasa Sakamoto ,  Maki Tawarada ,  Toshihisa Ohtsuka

    IPC分类号： C07K14/705 ,  C07K16/28 ,  C07H21/04 ,  C12P21/06

    CPC分类号： C07K14/47

    摘要： The present invention provides the mPrickle gene which encodes a protein present in mammalian PSD fractions. The mPrickle protein is localized in synapses, and binds to the scaffold protein PSD-95. Precipitation of endogenous mPrickle using an anti-mPrickle antibody results in the coprecipitation of NMDA receptors, and thus, mPrickle can be used in drug delivery systems that target NMDA receptors. NMDA receptors are closely related to learning and memory, and are also suggested to be involved in mental disorders. Thus, in the future, mPrickle is expected to be applicable to the diagnosis and/or treatment of neurodegenerative diseases associated with learning/memory, such as mental deterioration and dementia.

    摘要翻译： 本发明提供编码哺乳动物PSD级分中存在的蛋白质的mPrickle基因。 mPrickle蛋白定位在突触中，并结合到支架蛋白PSD-95。 使用抗mPrickle抗体沉淀内源性mPrickle导致NMDA受体的共沉淀，因此，mPrickle可用于靶向NMDA受体的药物递送系统。 NMDA受体与学习记忆密切相关，也被认为与精神障碍有关。 因此，将来，mPrickle预期适用于与学习/记忆相关的神经变性疾病的诊断和/或治疗，例如精神恶化和痴呆。

    Magnetic cell and method of using the same
    17.
    发明申请
    Magnetic cell and method of using the same 有权
    磁性细胞及其使用方法

    公开(公告)号：US20060264690A1

    公开(公告)日：2006-11-23

    申请号：US10554259

    申请日：2004-06-25

    申请人： Mitsuo Ochi

    发明人： Mitsuo Ochi

    IPC分类号： A61N2/00 ,  A61B19/00 ,  A61B17/52

    CPC分类号： C12N5/0006 ,  A61K41/00 ,  A61K47/6901

    摘要： In the present invention, because no examples are known of binding of magnetic particle to mesenchymal cell or chondrocyte which might be used in regenerative medicine, whether or not a cell having the magnetic particle bound thereto is retained in local by external magnetism after administration and whether or not the cell can exhibit intrinsic activity is studied. According to the present invention, a magnetic cell comprising mesenchymal cell or cultured chondrocyte having magnetic particle bound to the surface thereof is provided, and when the cell is administered in vivo and an external magnetic field is applied, the cell can be retained for a long time at a disease site. Moreover, a drug delivery system can be constructed by causing the magnetic cells to contain a drug.

    摘要翻译： 在本发明中，由于没有将磁性粒子与可能用于再生医学中的间充质细胞或软骨细胞结合的实例，是否具有与其结合的磁性粒子的细胞是否在给药后通过外部磁力保持在局部，以及是否 或者不能细胞可以表现出内在的活性被研究。 根据本发明，提供了包含具有与其表面结合的磁性粒子的间充质细胞或培养的软骨细胞的磁性细胞，并且当细胞在体内施用并施加外部磁场时，细胞可以保持长时间 在疾病现场的时间。 此外，可以通过使磁性细胞含有药物来构建药物递送系统。

    Lrp4/corin dopamine-producing neuron proliferation precursor cell marker
    18.
    发明申请
    Lrp4/corin dopamine-producing neuron proliferation precursor cell marker 审中-公开
    Lrp4 / corin多巴胺产生神经元增殖前体细胞标记

    公开(公告)号：US20060240432A1

    公开(公告)日：2006-10-26

    申请号：US10543003

    申请日：2004-01-23

    申请人： Yuichi Ono ,  Yasuko Nakagawa ,  Yoshimasa Sakamoto

    发明人： Yuichi Ono ,  Yasuko Nakagawa ,  Yoshimasa Sakamoto

    IPC分类号： C12Q1/68 ,  C12N5/08

    CPC分类号： C12Q1/6883 ,  C12Q2600/158

    摘要： In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.

    摘要翻译： 在神经元移植治疗中，在安全性方面，优选使用仅由期望类型的细胞组成的细胞群，并考虑使用神经元神经元以避免肿瘤发生的风险。 此外，考虑到移植后的生存力，适当的网络形成能力等，通过使用较早的祖细胞可以预期更大的治疗效果。 根据本发明，鉴定了在细胞周期退出之前在多巴胺能神经元增殖祖细胞中特异性表达的基因Lrp4。 在细胞中使用Lrp4表达作为指标，可以进行分离。 的细胞在安全性，存活率和网络形成能力方面适用于帕金森病等神经变性疾病的移植治疗。